Levi & Korsinsky Investigates Acquisition of Revance Therapeutics Inc. by Crown Laboratories, Inc.

NEW YORK, NY / ACCESS Newswire / February 18, 2025

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who own Revance Therapeutics Inc (“RVNC” or the “Company”) (NASDAQ:RVNC) Stock purchased prior to August 11, 2024.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. (“Crown”).

Revance Therapeutics Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, has been acquired by Crown Laboratories, a leading skincare company known for its dermatology products. This acquisition raises questions about the future direction of Revance and the potential impact on its shareholders.

Investors who purchased RVNC stock prior to August 11, 2024, may be concerned about the terms of the acquisition and whether they are receiving fair value for their investment. Levi & Korsinsky, LLP, a prominent securities litigation firm, is investigating the details of the acquisition to determine if any legal action is warranted on behalf of shareholders.

Revance Therapeutics has been at the forefront of developing innovative solutions for various medical conditions, including neurological disorders and aesthetic treatments. The acquisition by Crown Laboratories could signal a new chapter for the company, with potential synergies and opportunities for growth in the skincare and dermatology markets.

Shareholders of Revance are advised to stay informed about the investigation and to carefully consider their options moving forward. The outcome of the investigation could have significant implications for the future of Revance and its stakeholders.

How Will This Acquisition Affect Me?

As a shareholder of Revance Therapeutics Inc., the acquisition by Crown Laboratories may impact the value of your investment and the future prospects of the company. It is important to stay updated on the investigation by Levi & Korsinsky, LLP, and consider seeking legal advice if necessary to protect your interests.

How Will This Acquisition Affect the World?

The acquisition of Revance by Crown Laboratories could have broader implications for the biotechnology and skincare industries. It may lead to increased competition, innovation, and collaboration within these sectors, ultimately benefiting consumers with access to new and improved products and treatments.

Conclusion:

In conclusion, the investigation into the acquisition of Revance Therapeutics Inc. by Crown Laboratories, Inc. raises important questions about the fairness and implications of the deal. Shareholders and industry observers should monitor the developments closely to understand the potential impact on Revance, Crown, and the wider biotechnology and skincare markets.